Allspring Global Investments
CLDX icon

Allspring Global Investments’s Celldex Therapeutics CLDX Stock Holding History

Allspring Global Investments’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,941
Closed -$53.4K – 2316
2023
Q3 		$53.4K Buy
1,941
+805
+71% +$25.2K ﹤0.01% 2239
2023
Q2 		$38.5K Buy
1,136
+496
+78% +$16.7K ﹤0.01% 2349
2023
Q1 		$23K Buy
640
+49
+8% +$2.11K ﹤0.01% 2475
2022
Q4 		$26.3K Sell
591
-13
-2% -$464 ﹤0.01% 2529
2022
Q3 		$16K Sell
604
-1,799
-75% -$55.2K ﹤0.01% 2654
2022
Q2 		$64K Sell
2,403
-21,230
-90% -$617K ﹤0.01% 2183
2022
Q1 		$804K Buy
23,633
+334
+1% +$10.7K ﹤0.01% 2010
2021
Q4 		$900K Buy
+23,299
New +$1.02M ﹤0.01% 2005

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Allspring Global Investments's CLDX Position: Q4 2023 in Review

Allspring Global Investments sold out of Celldex Therapeutics (CLDX) in Q4 2023, closing a stake of 1,941 shares — an estimated $53.4K sold.

Allspring Global Investments first reported a position in CLDX in Q4 2021 and held it in 8 quarters. The position peaked at $900K in Q4 2021. 164 funds tracked by Wall St. Rank hold CLDX as of Q4 2023.

  • Allspring Global Investments reported no remaining Celldex Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 1,941 Celldex Therapeutics shares in Q4 2023, an estimated $53.4K.
  • Allspring Global Investments first reported a position in Celldex Therapeutics in Q4 2021 and held it in 8 quarters.
  • Allspring Global Investments's Celldex Therapeutics position peaked at $900K in Q4 2021.
  • 164 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.